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Background: The monoamine hypothesis has been recognized for over half a century as a 
reference point to understanding electrical dysfunction associated with disease states, and/or 
regulatory dysfunction related to synaptic, centrally acting monoamine concentrations (serotonin, 
dopamine, norepinephrine, and epinephrine).
Methods: Organic cation transporters (OCT) are a primary force controlling intracellular and 
extracellular (including synaptic) concentrations of centrally acting monoamines and their amino 
acid precursors. A new type of research was analyzed in this paper (previously published by the 
authors) relating to determining the functional status of the nutritionally driven organic cation 
transporters. It was correlated with the claims of the monoamine hypothesis.
Results: Results of laboratory assays from subjects not suffering from a hyperexcreting tumor 
show that centrally acting monoamine concentrations are indistinguishable in subjects with and 
without disease symptoms and/or regulatory dysfunction. Analysis of centrally acting monoam-
ine concentrations in the endogenous state reveals a significant difference in day-to-day assays 
performed on the same subject with and without monoamine-related disease symptoms and/or 
regulatory dysfunction. The day-to-day difference renders baseline testing in the endogenous 
state non-reproducible in the same subject.
Conclusion: It is asserted that the monoamine hypothesis, which claims that low synaptic 
levels of monoamines are a primary etiology of disease, is not a valid primary reference point 
for understanding chronic electrical dysfunction related to the centrally acting monoamines. 
Furthermore, the “bundle damage theory” is a more accurate primary model for understanding 
chronic dysfunction. The “bundle damage theory” advocates that synaptic monoamine levels 
are normal but not adequate in states associated with chronic electrical dysfunction and that 
levels need to be increased to compensate for the chronic postsynaptic electrical dysfunction 
due to existing damage. The monoamine hypothesis, in failing to accurately explain the   etiology 
of chronic neuronal electrical flow dysfunction in the endogenous state, is reduced to no more 
than a historical footnote.
Keywords: monoamine hypothesis, monoamine theory, serotonin, dopamine, neuronal 
  dysfunction, bundle damage theory
Introduction
This paper is the continuation of a series of original research papers published by the 
authors on the topic of nutritionally driven organic cation transporter (OCT) functional 
status determination (herein referred to as OCT assay[s]). This paper correlates original 
research previously published by the authors on the topic of transporter-driven centrally 
acting monoamine observations with the monoamine hypothesis.1–12
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The centrally acting monoamines serotonin,   dopamine, 
norepinephrine and epinephrine (herein referred to as 
“monoamine[s]”) exist in one of two states. The “  endogenous 
state” is present when no supplemental amino acids are being 
administered, and the “competitive inhibition state” is found 
when significant amounts of serotonin and/or dopamine 
amino acid precursors are simultaneously administered.1–7
Previous literature described the competitive inhibition 
state as “functionally meaningless.” The basis for this asser-
tion was the inability to alter monoamine levels with amino 
acid precursors and then objectively quantify the changes.7 
With the perfection of the novel OCT assay analysis by the 
authors, the competitive inhibition state is no longer function-
ally meaningless.1–12
Since the early 1960s, the monoamine hypothesis has 
been a reference point for understanding the etiology of 
the electrical defects associated with monoamine-related 
disease and the mechanism of action of reuptake inhibi-
tors. The monoamine hypothesis posits that depression is 
caused by decreased monoamine function in the brain. The 
hypothesis originated from early empirical clinical observa-
tions and has been generally recognized to mean that low 
concentrations of synaptic monoamines are a primary fac-
tor in the etiology of depression, other monoamine-related 
disease states, and regulatory dysfunction.13
The bundle damage theory was first published in 2009. It 
advocates that although synaptic levels of monoamines are 
normal in chronic monoamine-related disease states, these 
levels are inadequate in compensating for postsynaptic dam-
age to structures conducting electricity.8
In this manuscript, the new conclusions about 
  monoamine hypothesis and the bundle damage theory are 
compared with the original research of the authors. When 
inadequate levels of monoamines exist, the only way to 
increase the total number of monoamine molecules in 
the brain is through administration of their amino acid 
precursors. This is because monoamines do not cross the 
blood–brain barrier. The amino acid precursors can cross 
the barrier, and are synthesized into new monoamines. 
Whether the synaptic levels are lower than normal or 
normal at the start of management, nutritional status is a 
primary consideration in addressing problems associated 
with inadequate monoamines.4,6,10
There are two primary types of nutritional deficiencies. 
The monoamine hypothesis advocates that an absolute 
nutritional deficiency (AND) is the core issue of monoamine-
related electrical dysfunction, whereas the bundle damage 
theory advocates a relative nutritional deficiency (RND).8
An AND occurs when not enough nutrients are included 
in the diet, leading to nutritional concentrations that are not 
adequate for establishing normal synaptic monoamine levels 
(the monoamine hypothesis). A relative nutritional deficiency 
occurs when synaptic levels are normal in the endogenous 
state but not high enough to compensate for damage to the 
postsynaptic neuronal structures that conduct electricity (the 
bundle damage theory).
The organic cation transporters (OCT) are primary 
determinants of intracellular and extracellular (including 
synaptic) monoamine concentrations.13 Previously published 
literature by the authors provides proof that in the endo-
genous state transporter-dependent monoamine concentra-
tions are indistinguishable in subjects with and without 
monoamine-related disease and/or regulatory dysfunction. 
These findings are an integral part of the challenge to the 
validity of the monoamine hypothesis.4,6,10
Methods and materials
Original research results by the authors1–12 outlined a novel 
methodology for nutritionally driven OCT assay analysis that 
defines the phase of monoamine transport, status of trans-
porter entrance gates, transporter lumen saturation status, and 
transporter balance status between the monoamines and their 
amino acid precursors. These are all critical to determining 
whether the relative concentrations of the centrally acting 
monoamines are being effectively transported.1–12
Nutritionally driven OCT functional 
status determination
Under normal conditions, serotonin and dopamine filtered 
at the glomerulus are metabolized by the kidneys, which 
prevent significant amounts of these peripheral monoamines 
from being found in the final urine. Urinary serotonin and 
dopamine, in subjects not suffering from a monoamine-
secreting tumor, represent monoamines newly synthesized 
in the proximal convoluted renal tubule cells of the   kidneys. 
These monoamines have never been in the central or 
  peripheral systems. Once synthesized, their fate is depen-
dent upon the interaction of the basolateral monoamine 
transporters (OCT2) and the apical monoamine transporters 
(OCTN2). The OCT2 transports serotonin and dopamine 
to the   interstitium. These monoamines then end up in the 
peripheral system via the renal vein. The OCTN2 of the apical 
membrane transports the serotonin and dopamine not trans-
ported by the OCT2 to the proximal nephrons of the kidneys, 
before sending them to the urine as waste. Proper OCT assay 
requires that initially the serotonin and dopamine systems 
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are placed in the competitive inhibition state   simultaneously, 
while administering adequate amounts of serotonin and 
dopamine amino acid precursors. The assay results are then 
compared in order to determine the change in urinary sero-
tonin and dopamine concentrations associated with changes 
in amino acid precursor dosing values.2,3,5,6,11
A urinary serotonin or dopamine value less than 80 µg or 
475 µg of monoamine per gram of creatinine, respectively, 
is defined as a phase 2 response. A urinary serotonin or 
dopamine value greater than 80 or 475 µg of monoamine 
per gram of creatinine, respectively, is interpreted as being 
in phase 1 or phase 3. Differentiation of phase 1 from phase 
3 is as follows. If a direct relationship is found between 
amino acid dosing and urinary assay response, it is referred 
to as a phase 3 response. An inverse relationship is referred 
to as a phase 1 response. The phase 3 optimal range for 
urinary serotonin is defined as 80–240 µg of serotonin per 
gram of creatinine. The phase 3 optimal range for urinary 
dopamine is defined as 475–1,100 µg of dopamine per g of 
creatinine.2,3,5,6,11
Processing, management, and assay of the urine samples 
are as follows: urine samples are collected about 5–6 hours 
prior to bedtime, with 4:00 pm being the most frequent 
collection time point. The samples are stabilized in 6 N HCl 
to preserve the dopamine and serotonin. The urine samples 
are collected after a minimum of 1 week, during which 
time the patient has been taking a specific daily dosing of 
amino acid precursors of serotonin and dopamine where no 
doses are missed. Samples are shipped to DBS Laboratories 
(Duluth, MN). Urinary dopamine and serotonin are assayed uti-
lizing commercially available radioimmunoassay kits (3 CAT 
RIA IB88501 and IB89527, both from Immuno   Biological 
Laboratories Inc, Minneapolis, MN). The DBS   laboratory 
is accredited as a high-complexity laboratory by Clinical 
  Laboratory Improvement Amendments (CLIA) to perform 
these assays. OCT assay interpretation is performed by one of 
the authors (Marty Hinz, MD, NeuroResearch Clinics, Inc).
Results
The authors previously published “matched pairs t-test” 
results for the transporter-dependent, centrally acting mono-
amine concentrations in the endogenous state from the same 
subject on different days. This current paper is a continuation 
of this discussion based on original research that expands on 
the scope and implications of these scientific findings within 
the context of the monoamine hypothesis.4,6,10
In this previously published original research, spot 
  baseline urinary assays for each monoamine were obtained 
for the first test on day one and for the second test on a 
  different day. Both occurred at the same time of the day 
for each subject. The two tests from each subject were then 
paired, and a statistically significant grouping of matched 
pairs was subjected to the “matched pairs t-test.” The results 
are a critical component in forming the foundation of the 
conclusions in this paper.4,6,10
These original research studies reported that spot 
baseline urinary serotonin, dopamine, norepinephrine, and 
  epinephrine concentrations in the endogenous state differ in 
a statistically significant manner from day to day in the same 
subject. This supports the conclusion that under normal con-
ditions baseline urinary monoamine testing is not uniform or 
reproducible from day to day in the same subject. The func-
tional status of these organic cation transporters determines 
intracellular and extracellular (including synaptic) concentra-
tions of these monoamines. Furthermore, it was concluded 
that it is virtually impossible to distinguish, via laboratory 
assay interpretation, individuals with or without disease or 
regulatory dysfunctions, even those dysfunctions that were 
traditionally assumed to be associated with low levels of 
synaptic, centrally acting monoamine levels.4,6,10
Discussion
The monoamine hypothesis holds that low concentrations of 
synaptic monoamines are the primary etiology of monoam-
ine-related chronic electrical dysfunction.13 The corollary to 
this premise is that returning synaptic monoamine levels to 
normal will resolve electrical dysfunction. In correlating the 
perspective of the monoamine hypothesis with peer-reviewed 
literature published by the authors since 2009, the following 
considerations and conclusions exist.
Differentiation of those  
with and without disease
There is no objective proof demonstrating that low in situ 
levels of centrally acting monoamine concentrations in the 
synapse are the primary etiology under normal conditions.14 
There is no objective method that identifies individuals with 
low concentrations of transporter-dependent monoamine con-
centrations in the endogenous state.13   Transporter-  associated 
concentration trends in groups of subjects have been 
identified, but the day-to-day variability of monoamine 
concentrations in each individual comprising the group 
reveals that it is not possible to identify individuals with 
electrical dysfunction on laboratory testing and/or transporter 
analysis who are suffering from low levels of monoamines 
relative to the normal reference range.4,6,11 Diets devoid of 
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critical amino acids will induce an AND with associated 
disease symptoms, but diets such as this are not the normal 
endo  genous state of humans who develop monoamine or 
regulatory dysfunction-related symptoms.15,16
Synaptic monoamine concentrations are primarily 
dependent on the functional status of the nutritionally 
driven organic cation transporters. The monoamines and 
their amino acid precursors are “organic cations” that are 
transported by the three primary electrogenic organic cat-
ion transporter types, each of which has several subtypes: 
OCT1, OCT2, and OCT3. The OCT of the liver, brain, 
kidney, and bowels are identical and homologous.17 Of the 
three transporter types, the OCT2 has tissue expression 
primarily in the kidney and the brain.
OCT assay analysis has led to the ability to define the 
phases of monoamine transport, transporter saturation status, 
the status of monoamine and precursor transporter balance, 
the amount of waste (unneeded) monoamines the transporters 
are excreting, and the status of transporter entrance gates. 
After doing this OCT assay analysis, we can define the 
individualized amino acid dosing values needed for optimal 
flow of electricity through damaged postsynaptic bundles as 
evidenced by clinical outcomes.12,13
There is no objective documentation that identifies indi-
viduals with low concentrations of transporter-  dependent 
monoamine concentrations in the endogenous state. 
Transporter-associated concentration trends in groups of 
subjects have been identified, but the day-to-day variability of 
monoamine concentrations in each individual comprising the 
group reveals that it is not possible to identify individuals with 
electrical dysfunction on laboratory testing and/or transporter 
analysis who are suffering from low levels of monoamines 
relative to the normal reference range. 4,6,10
In the endogenous state, under the monoamine   hypothesis, 
low synaptic concentrations of monoamines are a primary 
cause of electrical dysfunction.14 If this were true, the sig-
nificant fluctuations in transporter-dependent monoamine 
concentrations from day to day in the individual should lead 
to clinical states where the findings would wax and wane in 
a manner consistent with day-to-day observed fluctuations in 
transporter-driven monoamine concentrations as documented 
in same subject studies (matched pairs t-test). This is not the 
case. The etiology of chronic problems is not low concentra-
tions of monoamines that need to be returned to normal as 
predicted by the monoamine hypothesis; it is concentrations 
that are normal but not high enough to compensate for post-
synaptic neuronal damage. Addressing this electrical defect 
properly requires the system to be placed into the competitive 
inhibition state in order to be able to increase monoamine 
levels to above normal to reach the threshold level needed to 
establish the adequate electrical flow required. Analysis of 
transporter-driven monoamine needs reveals that post  synaptic 
electrical conduction damage in patients with chronic disease 
is so high that the day-to-day monoamine fluctuations of the 
endogenous state are below the threshold needed to attain 
symptom relief. Therefore, chronic symptoms do not wax and 
wane as might be predicted by the laboratory results obtained 
in the endogenous state.5,8   Previous writings of the authors 
demonstrated relative nutritional deficiencies in Parkinson’s 
disease,5 chronic depression,9,12 Crohn’s disease,2 and atten-
tion deficit hyperactivity disorder without any findings that 
would support an AND.3   Restoration of regulatory function 
in these RND conditions is only possible when transporter-
dependent monoamine concentrations are elevated above 
normal and properly balanced in the competitive inhibition 
state (see Figure 1).1–12
Many disease states have been recognized as having a 
common etiology of postsynaptic bundle damage associ-
ated with insult.1–12 Different areas of damage to the nerve 
bundles result in different disease entities. These entities 
all share a common pathology of inadequate levels of the 
monoamine-driven electrical activity that is required to 
power the functions of the body. This results in the rela-
tive nutritional deficiency that requires monoamine levels 
higher than normally found in the synapse to overcome 
the damaged areas of the nerve bundles. Parkinson’s 
disease demonstrates this deficiency and the ability of 
targeted amino acid precursor supplementation to restore 
function.5
Parkinson’s disease as a prototype
Parkinson’s disease is a prototype disease that illustrates the 
mechanism of action of postsynaptic neuron damage and its 
compensation. Chronic damage to the postsynaptic dopamine 
fibers of the substantia nigra induce an RND that is not just 
dopamine related but is related to all of the centrally acting 
monoamines. This RND causes Parkinson’s disease symp-
toms by compromising the flow of electricity regulating fine 
motor control. The monoamine levels of Parkinson’s patients 
prior to treatment are found to be in the normal range. Proper 
management of Parkinson’s disease requires an increase in 
the synaptic levels of dopamine with a higher than normal 
administration of L-dopa. Increasing the synaptic neurotrans-
mitter with L-dopa is analogous to turning up the voltage. It 
causes more electricity to flow through the remaining viable 
postsynaptic, electricity-conducting neuronal structures. 
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When enough electricity is once again flowing, control of 
symptoms is effected.5
Dietary management
The monoamines do not cross the blood–brain barrier. 
The only way to increase the total number of monoamine 
  molecules in the brain – to a level that is higher than is possible 
with dietary modification – is with supplemental   nutritional 
support through administration of properly balanced amino 
acid precursors and cofactors. These cross the blood–brain 
barrier and are synthesized into new monoamines.1–12
The immediate amino acid precursors of serotonin and 
dopamine, 5-HTP and L-dopa, respectively, freely cross 
the blood–brain barrier to synthesize into their respective 
  monoamines without biochemical feedback inhibition 
(Figure 2). At equilibrium the amino acid precursors have 
a similar effect on all identical and homologous OCTs and 
subtypes throughout the body.12
When synapse-related electrical compromise is present, 
the monoamine hypothesis advocates that an AND exists, 
ie, low synaptic monoamine levels are present and return-
ing these levels to normal will restore adequate electrical 
flow. This would predict that an optimized normal diet, 
with no supplemental nutrients, will restore the low levels 
of synaptic monoamines back to normal, leading to relief 
of the electrical dysfunction that is causing the disease or 
regulatory dysfunction. This does not happen. Literature has 
not described dietary modification as a valid and/or effective 
approach in management of monoamine-related synaptic 
electrical dysfunction under normal conditions.
Under the bundle damage theory, as discussed in the next 
section, when neuronal electrical compromise (due to postsyn-
aptic damage) is significant, a relative nutritional deficiency 
is concomitantly present. Proper compensation requires that 
the system be placed in the competitive inhibition state where 
synaptic monoamine levels are higher than normal; this cannot 
be achieved with dietary modification alone. Administration 
of properly balanced supplemental amino acid precursors 
under the guidance of OCT assay analysis is needed. This 
ensures proper amino acid and monoamine transport balance 
and compensates for the electrical defect.
The balance between serotonin precursors, dopamine 
  precursors, and sulfur amino acids is critical, as profound 
interactions exist between these substances. When administra-
tion of these substances is not in proper balance, an additional 
amino acid-induced RND develops (see Figure 1).1–12
There are many things that can be gleaned out of Figure 1, 
such as administering only 5-HTP facilitates depletion of 
dopamine. Giving only L-dopa facilitates depletion of sero-
tonin, sulfur amino acids, L-tyrosine, and L-tryptophan.
The administration of properly balanced 5-HTP with 
L-dopa establishes transporter-dependent synaptic mono-
amine concentrations at levels higher than normal. These 
levels compensate for the relative nutritional deficiency 
and resultant electrical deficit.18 In contrast, the monoam-
ine hypothesis has never demonstrated that under normal 
conditions returning synaptic monoamine levels to normal 
is effective.
The bundle damage theory
Under the bundle damage theory, relative nutritional defi-
ciency is the cause of chronic electrical dysfunction observed 
with centrally acting monoamine-related problems. This is 
supported by the fact that in the endogenous state all subjects 
with and without disease have similar and indistinguish-
able monoamine levels. The primary source of the chronic 
electrical dysfunction under the bundle damage theory is 
damage to the postsynaptic structural components involved 
with electrical conduction. In this state, the levels of synaptic 
monoamines are normal and an RND exists.8
A list of almost 1200 known neurotoxins found in the 
environment serves as a backdrop for this discussion.19 
Neurotoxins, trauma, biologics, and/or genetic predisposi-
tion contribute to postsynaptic structural damage which 
compromises electrical flow when synaptic monoamine 
levels are normal. This damage tends to be cumulative. 
The flow of electricity between the pre- and postsynaptic 
neurons is mediated by synaptic levels of centrally acting 
monoamines. This causes electrically dependent functions 
to be improperly regulated.5,8
Individual dendrite structures of postsynaptic neu-
rons do not facilitate electrical flow as a single entity. 
Multiple postsynaptic structures, functioning as bundles, 
regulate function. The bundle damage theory states that a 
significant factor in the development of monoamine-related 
electrical dysfunction disease or regulatory dysfunction 
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Figure 1 If dopamine precursors (L-tyrosine and/or L-dopa) are not in proper 
balance  with  serotonin  precursors  (5-HTP  and/or  L-tryptophan),  depletion  of 
serotonin or dopamine will occur. All components of the system need to be in 
proper balance.
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occurs when the electrical flow through the postsynaptic 
neuron bundles regulating function is compromised by 
  damage. In order to optimally restore neuron bundle regu-
latory function, synaptic neurotransmitter levels involved 
with transference of electrical flow across the synapse into 
the remaining viable postsynaptic neuron structures must 
be increased to levels higher than are normally found in 
the system. This in turn results in restoration of adequate 
electrical flow, relief of symptoms, and/or resolution of 
regulatory dysfunction.8
Support for the bundle damage theory is that restoration 
of normal neuronal electrical flow can be accomplished by 
increasing monoamine concentrations into the competitive 
inhibition state, where organic cation transporter-driven and 
synaptic monoamine concentrations are higher than those 
found in the endogenous state. The situation is managed as a 
relative nutritional deficiency. Instead of ascribing the symp-
tom etiology to low concentrations of transporter-dependent 
synaptic monoamines in chronic states, it is more accurate 
to attribute the cause to synaptic monoamine concentrations 
being chronically inadequate to compensate for electrical 
dysfunction induced by postsynaptic structural damage. 
When chronic monoamine-related deficiency states exist, this 
terminology more appropriately explains the need to increase 
synaptic monoamine concentrations into the competitive 
inhibition state.4,6,10
The World Health Organization’s observation, consistent 
with the bundle damage theory, is that higher toxicant expo-
sure (in developed countries) contributes to the higher rate of 
depression and other monoamine-related disease.8
Relative nutritional deficiency, secondary to postsynaptic 
structural damage, may be the only issue in which proper 
management allows for removing the RND from the clinical 
picture. This is to ensure that any other possible concomitant 
disease and regulatory dysfunction etiologies or mechanisms 
of action may be focused on more clearly.
Reuptake inhibitors
The mechanism of action of reuptake inhibitors is unknown, 
but it is theorized that blocking of transporter reuptake leads 
to increased concentrations of synaptic monoamines and 
restoration of electrical flow. Reuptake inhibitor efficacy in 
the treatment of depression is low. Double-blind, placebo-
controlled studies consistently reveal reuptake inhibitor 
depression efficacy of 7% to 13% greater than placebo. 
From another perspective, this means 87% to 93% of 
patients treated with reuptake inhibitors for depression 
can expect to achieve results no greater than placebo. The 
authors previously reported the novel findings that the 
effects of reuptake inhibitors on transporter-driven mono-
amine concentrations revealed serotonin concentrations 
changed ,50 µg/gr creatinine. These very small OCT-
driven changes in monoamine concentrations are consistent 
with the low efficacy of the reuptake inhibitors. Group 
analysis shows no statistical significance.9,18
If simply establishing synaptic monoamine concentra-
tions in the normal range under an absolute nutritional defi-
ciency approach as predicted by the monoamine hypothesis 
were all that is required, it would be expected that reuptake 
inhibitor efficacy would be higher than reported. This is 
not the case. In previously published manuscripts by the 
authors, subjects with depression were managed under the 
relative nutritional deficiency approach using monoamine 
precursor nutritional support with 5-HTP and L-dopa which 
elevated the mean serotonin and dopamine concentrations 
higher than normal into the desired competitive inhibition 
phase 3 range, leading to restoration of electrical flow. 
This procedure produced magnitudes of increased levels 
of the transporter-driven serotonin and dopamine concen-
trations, far beyond the increases observed with reuptake 
inhibitors alone.1–12
The required serotonin and dopamine precursor dosing 
values are independent of each other in the competitive inhi-
bition state. Optimal daily ranges exist when all monoamine-
related diseases are examined in the competitive inhibition 
state. Some variances of the high end of the range may occur 
when the individual diseases are examined. The 5-HTP 
daily effective therapeutic range is .0 mg to 2400 mg. The 
L-dopa daily effective therapeutic range (in subjects not suf-
fering from Parkinson’s disease or Restless Leg Syndrome) 
is .0 mg to 2100 mg. The tyrosine daily effective therapeutic 
range is .0 mg to 14,000 mg.1–12
L-tryptophan
L-tyrosine L-dopa Dopamine
Amino acids
5-HTP Serotonin
Norepinephrine Epinephrine
Monoamine neurotransmitters
Figure 2 The centrally acting monoamines with their amino acid precursors.
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Table 1 A comparison of the monoamine hypothesis and the bundle damage theory
Monoamine hypothesis Bundle damage theory
Synaptic monoamine levels when  
electrical dysfunction exits
Low Normal
Neuronal system status Normal Postsynaptic structural damage leading to  
compromised electrical flow
Monoamine levels required  
to restore electrical flow
Normal (endogenous state) Higher than normal (competitive inhibition state)
Etiology Nutritional deficiency Recurrent damage due to neurotoxins, trauma,  
biologics and/or genetic predisposition
Conclusion on the 
basis of the etiology
Absolute nutritional deficiency, dietary modification  
(no supplements) will correct the problem
Relative nutritional deficiency, properly  
balanced supplementation needed to establish  
monoamine levels higher than normal
Laboratory observations From a laboratory standpoint, in the endogenous state, 
unable to distinguish those with and without disease  
contrary to predictions of the monoamine hypothesis
OCT assay determination in the competitive  
inhibition state allows for predictable outcomes  
to nutritionally driven monoamine changes
Undermining the concept Literature has never described dietary modification  
that simply returns synaptic monoamine levels  
to normal as a valid approach in management of  
monoamine-related electrical dysfunction
None
Support for the concept Empirical observations that increasing synaptic  
monoamine levels leads to clinical improvement  
without proof that simply returning monoamine  
levels to normal is what is happening
Published literature on difficult to treat cases of  
Parkinson’s disease, chronic depression, Crohn’s  
disease, attention deficit hyperactivity disorder,  
where synaptic levels are initially normal then  
intentionally increased to higher than normal  
to compensate for chronic electrical damage
Abbreviation: OCT, organic cation transporter.
Table 1 juxtaposes the monoamine hypothesis against the 
bundle damage theory.
Conclusion
The authors of this manuscript have published more than a 
dozen peer-reviewed papers on the topic of centrally acting 
monoamines and administration of their precursors. This 
paper correlates previous original research findings of the 
authors with the monoamine hypothesis and is a continuation 
of the scientific discussion.1–12 While there has been previous 
literature that has discredited the monoamine hypothesis, this 
paper sheds further light on the topic.
The monoamine hypothesis is based on the assumption 
that synaptic concentrations of monoamines are lower than 
normal in monoamine-related, central neuronal electrical 
dysfunction states. This supports the assertion that addressing 
the problem under an absolute nutritional deficiency strategy 
by returning synaptic monoamine concentrations to normal 
would be effective. The contents of this paper prove that this 
does not happen.13
The bundle damage theory states that monoamine con-
centrations are normal but not adequate, due to an RND 
in subjects with and without chronic disease. In order to 
restore adequate electrical flow and compensate for post-
synaptic damage, organic cation transporter-driven synaptic 
monoamine levels must be increased to a level greater than 
those concentrations found in the endogenous state, under a 
monoamine amino acid RND approach outlined in previous 
peer-reviewed original research publications.8
The key difference between the monoamine hypothesis 
and the bundle damage theory is the perception that electri-
cal dysfunction is caused by low synaptic concentrations 
of monoamines versus normal synaptic concentrations of 
monoamines that are not high enough to compensate for 
postsynaptic structural damage.
Analysis of monoamine concentrations in subjects 
in the endogenous state with and without the presence 
of   monoamine-related electrical dysfunction reveals that 
it is impossible to differentiate these subjects based on 
laboratory testing.4,6,10
Reuptake inhibitors have low efficacy in the treatment 
of monoamine-related disease. Their focus is treatment of 
the disease without addressing the proper balance of mono-
amines and precursors required under the relative nutritional 
deficiency approach. This is consistent with findings that 
reuptake inhibitors cause no statistically significant changes 
in transporter-dependent monoamine concentrations.12
In chronic disease states the leading cause of electri-
cal dysfunction is monoamine-related RND, secondary 
to damage to postsynaptic neuronal structures caused by 
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  neurotoxins, trauma, biologics, and/or genetic predisposition. 
The only way to compensate for damaged electrical flow is to 
properly balance serotonin and dopamine in the competitive 
inhibition state through administration of amino acid precur-
sors under the guidance of OCT assay determination.2,3,5,7,8
Postsynaptic electrical dysfunction may not be the only 
etiology of monoamine-related dysfunction. Proper admin-
istration of serotonin and dopamine amino acid precursors, 
under the guidance of OCT assay determination, removes con-
cerns of RND from the clinical picture, facilitating the ability 
to clearly focus on other possible etiologies as needed.
The monoamine hypothesis is simply not a valid concept. 
It is the goal of this manuscript to stimulate interest and 
dialogue regarding the etiology of synaptic monoamine-
associated electrical dysfunction.
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